Skip to main content
Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Introducing the Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
February 13, 2024

Syn-One Test® Features Prominently in NeurologyLive MEDcast Episode

NeurologyLive’s MEDcast recently released an episode titled “Paradigm Shift in Parkinson’s Disease Diagnosis” that included…
Insights
February 7, 2024

The Role of Environmental Toxins in Parkinson’s Disease Risk

As 2023 drew to a close, the Parkinson’s community worked together to bring important legislation…
Insights
January 11, 2024

Minimally Invasive, Maximally Important

Neurodegenerative diseases like Parkinson’s and dementias continue to represent some of the most significant threats…
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

On Our Radar
February 19, 2024

Alterity Therapeutics to Continue Phase 2 Study of ATH434 in Multiple System Atrophy

After a prespecified review by an independent Data Monitoring Committee (DMC) found no safety concerns,…
On Our Radar
January 24, 2024

Genetic Mutation Reduces Risk of Parkinson’s Disease by Half

Researchers at the University of Southern California Leonard Davis School of Gerontology announced last week…
On Our Radar
January 19, 2024

Robotic Exosuit Eliminates Gait Freezing in Man With Parkinson’s

Annovis Bio announced that it has completed the final patient study visit in its Phase…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our free Skin Biopsy Test Kit, simply collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit